Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Verma A, Chi YY, Malvar J, Lamble A, Chaudhury S, Agarwal A, Li HT, Liang G, Leong R, Brown PA, Kaplan J, Schafer ES, Slone T, Pauly M, Chang BH, Stieglitz E, Wayne AS, Hijiya N, Bhojwani D. Verma A, et al. Among authors: wayne as. Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496. Cancers (Basel). 2024. PMID: 38339248 Free PMC article.
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
Schafer ES, Rushing T, Crews KR, Annesley C, Colace SI, Kaiser N, Pommert L, Ramsey LB, Sabnis HS, Wong K, Chang BH, Cooper TM, Shah NN, Rheingold SR, Place AE, Chi YY, Bhojwani D, Wayne AS, Bernhardt MB. Schafer ES, et al. Among authors: wayne as. J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165. J Natl Cancer Inst. 2024. PMID: 38964343
Enhancing pediatric access to cell and gene therapies.
Mackall CL, Bollard CM, Goodman N, Carr C, Gardner R, Rouce R, Sotillo E, Stoner R, Urnov FD, Wayne AS, Park J, Kohn DB. Mackall CL, et al. Among authors: wayne as. Nat Med. 2024 Jul;30(7):1836-1846. doi: 10.1038/s41591-024-03035-1. Epub 2024 Jun 17. Nat Med. 2024. PMID: 38886624 Review.
Feasibility and Favorable Responses Following Investigational CAR T-Cell Therapy for Relapsed and Refractory Infant ALL.
Annesley C, Lamble AJ, Summers C, Pulsipher MA, Wayne AS, Rivers J, Huang W, Wilson A, Wu Q, Seidel KD, Mgebroff S, Brown CT, Lindgren C, Park JR, Jensen MC, Gardner RA. Annesley C, et al. Among authors: wayne as. Blood Adv. 2024 Aug 12:bloodadvances.2024012638. doi: 10.1182/bloodadvances.2024012638. Online ahead of print. Blood Adv. 2024. PMID: 39133891
CD33-CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-targeting CAR-T cells.
Jambon S, Sun J, Barman S, Muthugounder S, Bito XR, Shadfar A, Kovach AE, Wood BL, Thoppey Manoharan V, Morrissy AS, Bhojwani D, Wayne AS, Pulsipher MA, Kim YM, Asgharzadeh S, Parekh C, Moghimi B. Jambon S, et al. Among authors: wayne as. Blood Cancer Discov. 2024 Dec 3. doi: 10.1158/2643-3230.BCD-23-0258. Online ahead of print. Blood Cancer Discov. 2024. PMID: 39624992
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Wayne AS, Huynh V, Hijiya N, Rouce RH, Brown PA, Krueger J, Kitko CL, Ziga ED, Hermiston ML, Richards MK, Baruchel A, Schuberth PC, Rossi J, Zhou L, Goyal L, Jain R, Vezan R, Masouleh BK, Lee DW. Wayne AS, et al. Haematologica. 2023 Mar 1;108(3):747-760. doi: 10.3324/haematol.2022.280678. Haematologica. 2023. PMID: 36263840 Free PMC article.
136 results